Boston Scientific Corp (BSX)vsMyomo Inc (MYO)
BSX
Boston Scientific Corp
$42.98
-0.28%
HEALTHCARE · Cap: $62.29B
MYO
Myomo Inc
$1.30
0.00%
HEALTHCARE · Cap: $55.45M
Smart Verdict
WallStSmart Research — data-driven comparison
Boston Scientific Corp generates 48432% more annual revenue ($21.00B vs $43.26M). BSX leads profitability with a 17.5% profit margin vs -33.5%. BSX earns a higher WallStSmart Score of 72/100 (B).
BSX
Strong Buy72
out of 100
Grade: B
MYO
Avoid29
out of 100
Grade: F
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-10.0%
Fair Value
$39.07
Current Price
$42.98
$3.91 premium
Intrinsic value data unavailable for MYO.
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Large-cap with strong market position
Growing faster than its price suggests
Attractively priced relative to earnings
Reasonable price relative to book value
Strong operational efficiency at 22.9%
Generating 1.3B in free cash flow
Revenue surging 21.3% year-over-year
Areas to Watch
Distress zone — elevated risk
Trading at 8.7x book value
0.0% earnings growth
Smaller company, higher risk/reward
Weak financial health signals
Comparative Analysis Report
WallStSmart ResearchBull Case : BSX
The strongest argument for BSX centers on Market Cap, PEG Ratio, P/E Ratio. Profitability is solid with margins at 17.5% and operating margin at 22.9%. PEG of 0.60 suggests the stock is reasonably priced for its growth.
Bull Case : MYO
The strongest argument for MYO centers on Revenue Growth. Revenue growth of 21.3% demonstrates continued momentum.
Bear Case : BSX
The primary concerns for BSX are Altman Z-Score.
Bear Case : MYO
The primary concerns for MYO are Price/Book, EPS Growth, Market Cap. Debt-to-equity of 3.44 is elevated, increasing financial risk.
Key Dynamics to Monitor
BSX profiles as a mature stock while MYO is a growth play — different risk/reward profiles.
MYO carries more volatility with a beta of 1.50 — expect wider price swings.
MYO is growing revenue faster at 21.3% — sustainability is the question.
BSX generates stronger free cash flow (1.3B), providing more financial flexibility.
Bottom Line
BSX scores higher overall (72/100 vs 29/100), backed by strong 17.5% margins. Both earn "Strong Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Boston Scientific Corp
HEALTHCARE · MEDICAL DEVICES · USA
Boston Scientific Corporation, doing business as Boston Scientific, is a manufacturer of medical devices used in interventional medical specialties, including interventional radiology, interventional cardiology, peripheral interventions, neuromodulation, neurovascular intervention, electrophysiology, cardiac surgery, vascular surgery, endoscopy, oncology, urology and gynecology.
Myomo Inc
HEALTHCARE · MEDICAL DEVICES · USA
Myomo, Inc., a portable medical robotics company, designs, develops and produces myoelectric braces for people with neuromuscular disorders in the United States. The company is headquartered in Boston, Massachusetts.
Compare with Other MEDICAL DEVICES Stocks
Want to dig deeper into these stocks?